Lipella Pharmaceuticals, Inc. (LIPO) Price & Analysis

Compare

109 Followers

LIPO Stock Chart & Stats

$0.22

-$0.15(-4.71%)

At close: Jan 08 4:00 PM EST

$0.22

-$0.15(-4.71%)

Day’s Range― - ―

52-Week Range$0.21 - $7.31

Previous CloseN/A

Volume96.41K

Average Volume (3M)7.72K

Market Cap

$993.48K

Enterprise ValueN/A

Total Cash (Recent Filing)$1.86B

Total Debt (Recent Filing)$264.08M

Price to Earnings (P/E)―

Beta-0.48

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.78

Shares Outstanding4,620,837

10 Day Avg. Volume11,317

30 Day Avg. Volume7,716

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)1.67

Price to Sales (P/S)5.96

P/FCF Ratio-0.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsLipella announced positive results from its P2a study of LP-310 in oral lichen planus, demonstrating significant improvements across key symptoms, including reductions in pain, ulceration, and inflammation.

Regulatory ProgressFDA granted approval for an expanded access program for LP-310, its oral rinse formulation of tacrolimus, for the treatment of oral lichen planus.

Bears Say

Financial NeedsThe company will likely need to raise additional capital to fund its ongoing programs.

Lipella Pharmaceuticals, Inc. News

Lipella Pharmaceuticals Announces CMO Retirement

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) just unveiled an announcement. On October 3, 2025, Dr. Michael Chancellor announced...

2M ago

LIPO

Lipella Pharmaceuticals Announces Positive Phase 2a Results

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has provided an update. On September 18, 2025, Lipella Pharmaceuticals announced positive...

3M ago

LIPO

Lipella Pharmaceuticals announces final results from Phase 2a study of LP-10

Lipella Pharmaceuticals (LIPO) announced final results from its completed Phase 2a multicenter, dose-ranging study evaluating LP-10, a proprietary...

3M ago

LIPO

Lipella Pharmaceuticals Announces Nasdaq Delisting

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has shared an announcement. On June 25, 2025, Lipella Pharmaceuticals announced its...

6M ago

LIPO

Lipella Pharmaceuticals Faces Nasdaq Delisting

Lipella Pharmaceuticals, Inc. ( ($LIPO) ) has issued an announcement. On June 20, 2025, Lipella Pharmaceuticals announced that...

6M ago

LIPO

Lipella Pharmaceuticals announces U.S. patent issuance for diagnostic tech

Lipella Pharmaceuticals (LIPO) announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial...

6M ago

LIPO

Lipella Pharmaceuticals Announces 2025 Stockholders Meeting Date

An announcement from Lipella Pharmaceuticals, Inc. ( ($LIPO) ) is now available. Lipella Pharmaceuticals Inc. has announced its...

6M ago

LIPO

Lipella Pharmaceuticals re-signs manufacturing collab with Cook MyoSite

Lipella Pharmaceuticals (LIPO) announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry,...

7M ago

LIPO

Lipella Pharmaceuticals Faces Nasdaq Compliance Challenge

The latest update is out from Lipella Pharmaceuticals, Inc. ( ($LIPO) ). On May 12, 2025, Lipella Pharmaceuticals...

7M ago

LIPO

Lipella Pharmaceuticals Presents Promising Phase 2a Trial Data

An announcement from Lipella Pharmaceuticals, Inc. ( ($LIPO) ) is now available. On May 15, 2025, Lipella Pharmaceuticals...

7M ago

LIPO

Lipella Pharmaceuticals to present Phase 2a data for LP-310

Lipella Pharmaceuticals (LIPO) announced that topline data from the first two dose cohorts of its ongoing Phase 2a...

7M ago

LIPO

Lipella Reports Statistically Significant Results from Second Cohort in LP-310 Phase 2a Trial for Oral Lichen Planus

Pittsburgh, Pennsylvania, USA, April 23rd, 2025, Chainwire Findings reinforce localized efficacy profile; topline data from final dose group...

8M ago

LIPO

Lipella abstract on LP-10 for OLP accepted for presentation at AAOM, EAOM

Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has...

8M ago

LIPO

Lipella Pharmaceuticals announces results from second cohort of LP-310 trial

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating...

8M ago

LIPO

LIPO FAQ

What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?

Lipella Pharmaceuticals, Inc. lowest stock price was $0.21 and its highest was $7.31 in the past 12 months.

What is Lipella Pharmaceuticals, Inc.’s market cap?

Lipella Pharmaceuticals, Inc.’s market cap is $993.48K.

When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?

Currently, no data Available

Is Lipella Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lipella Pharmaceuticals, Inc. pay dividends?

Lipella Pharmaceuticals, Inc. does not currently pay dividends.

What is Lipella Pharmaceuticals, Inc.’s EPS estimate?

Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lipella Pharmaceuticals, Inc. have?

Lipella Pharmaceuticals, Inc. has 4,620,837 shares outstanding.

What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in LIPO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.